Delivery Order SPE2DB22D3009-SPE2DB25FBD34
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,322.47 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and will be performed at the awardee's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,847.74 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement requirements. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $14,136.53 for RINVOQ ER 15 mg tablets (30-count units) on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $18,279.31 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed price, competitively awarded contract without set-aside designation represents a single delivery order under AmerisourceBergen's larger federal pharmaceutical supply framework. The product will be performed at the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $10,772.76 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on July 25, 2025, with completion expected by July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a procurement of pharmaceutical inventory supporting military healthcare operations. The contract carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $15,148.25 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 24, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $17,598.50 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 1, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on July 21, 2025, with a completion date of July 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a small-value pharmaceutical supply transaction. The award was placed of performance at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order operates...
- The Defense Logistics Agency awarded a delivery order valued at $3,713.81 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count unit dose), effective August 4, 2025, with completion by August 5, 2025. This non-competitive, firm fixed-price delivery order represents a routine pharmaceutical supply transaction under the company's broader contract vehicle with DLA. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBD34Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,906.25 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with an ultimate completion date of August 18, 2025. This firm fixed-price contract, awarded without a set-aside designation on August 15, 2025, represents a competitively awarded procurement supporting the federal medical supply chain. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The company's extensive federal contract portfolio demonstrates its established capability to fulfill diverse pharmaceutical procurement requirements through open competition and across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 8/15/25 |